Purpose & innovation

Because patients deserve better.

For many patients, the journey through cancer treatment can feel overwhelming. They fear their cancer, but also the side effects of treatment.

While conventional therapies have saved countless lives, their impact can leave patients struggling with severe and debilitating adverse effects that can last long after treatment is complete. At Mariana Oncology, a Novartis Company, we believe patients deserve better.

Mariana Oncology is advancing a new generation of precision radioligand therapies that represent a revolutionary approach to cancer treatment. These novel medicines combine two important components:

  • A targeting moiety that seeks out proteins found primarily on cancer cells
  • A radioisotope to precisely deliver cancer-killing radiation

Together, these components are expected to ensure the therapeutic is targeted and delivered directly to diseased cells while limiting the effects of the treatment on otherwise healthy or normal cells.

Educational video about Mariana Oncology’s radioligand therapies and how they interact with tumor cells

Engineering the next generation of precision radioligand therapies

Designed with intention

We design, develop, and manufacture precision radioligand therapies with the potential to transform cancer treatment, maintaining focus on the patient experience throughout the development process.

Innovative target
selection

Developing precision radioligand therapies starts with selection of novel targets to address immunologically silent, radiosensitive tumors. We identify compelling therapeutic targets with the potential to unlock treatment for not just one but a broad range of cancers.

Precision drug
design

​​Our in-house lead discovery, peptide chemistry, radiochemistry, and radiopharmacology expertise allows us to rapidly screen, design, make, and test novel macrocyclic peptides for selective targeting and optimal tumor penetration.

Proactive product
development

We design our drug candidates to have potential best-in-class profiles by selecting the ideal radioisotope for each target; optimizing design components of the molecule for enhanced potency and tumor penetration; and optimizing formulation and stability to ensure the global reach of our therapeutics.

De-risking in early
development

Ligand compatibility with therapeutic and imaging radioisotopes allows de-risked development via early clinical studies evaluating target engagement and radiation dosimetry, and offers opportunities to identify patients most likely to benefit from our radioligand therapies.

Robust supply &
manufacturing

We have built in-house GMP capabilities and secured access to a broad radioisotope supply in order to support rapid R&D and clinical development for a broad product portfolio.
Mariana Oncology, a Novartis Company, logo

In partnership with our colleagues at Novartis, we are leading the development of precise radioligand therapies, charting the path toward a future in which patients around the world will have access to potentially life-changing medicines.

Mariana Oncology scientist in a blue lab coat works in the laboratory
Wave shape

Expanding innovation & impact

Mariana Oncology, a Novartis company, has established a Radioligand Therapy Innovation Center of Excellence, bringing together expertise across research, manufacturing, and early development to fuel innovation and collaboration within the industry. These capabilities facilitate rapid design, development, and clinical testing of radioligand therapies to bring novel treatments to the patients who urgently need them.

We strive to partner with both physicians and patients to deliver transformative therapies that meaningfully impact lives.

Advancing a pipeline of novel therapies

Discover our programs